A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Background: Patients with advanced colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback